Key result
Integrating baseline high-sensitivity cardiac troponin I, global longitudinal strain, and coronary artery calcium improved risk stratification for cancer therapy-related cardiac dysfunction, achieving an AUC of 0.91 compared to 0.66 for ejection fraction alone.
Why the study?
Anthracycline-related cardiac dysfunction in multiple myeloma is a major concern, and conventional LVEF surveillance may miss early cardiac injury.
Does integrating baseline hs-cTnI, global longitudinal strain, and coronary artery calcium improve risk stratification for anthracycline-related cardiac dysfunction in multiple myeloma patients compared to conventional LVEF surveillance?
Observational (n=312)
Blinded outcome assessment
No
Does integrating baseline hs-cTnI, global longitudinal strain, and coronary artery calcium improve risk stratification for anthracycline-related cardiac dysfunction in multiple myeloma patients compared to conventional LVEF surveillance?
Answers are grounded in this paper and cite their sources.
Integrating baseline measurements of hs-cTnI, global longitudinal strain, and coronary artery calcium into a simple risk score significantly improves early prediction of anthracycline-related cardiotoxicity compared to standard LVEF monitoring.
Background Anthracycline-related cardiac dysfunction remains a major concern in multiple myeloma, yet conventional left ventricular ejection fraction (LVEF) surveillance may miss early injury. We evaluated whether pre-anthracycline baseline measurements of high-sensitivity cardiac troponin I (hs-cTnI), global longitudinal strain (GLS), and coronary artery calcium (CAC), obtained before anthracycline initiation, improve risk stratification for cancer therapy-related cardiac dysfunction (CTRCD). Methods In this retrospective study of 312 myeloma patients receiving anthracycline-based therapy, CTRCD was defined as LVEF decline >10% to <53% or relative GLS decline >15%. Predictive performance was assessed using competing-risk models and time-dependent ROC analysis. A simplified risk score (MY-CARD) was derived and temporally validated in a separate cohort. Results CTRCD occurred in 91 patients (29.2%). hs-cTnI elevation and GLS worsening preceded LVEF decline, with median intervals of 8.4 and 12.6 weeks. The full model (hs-cTnI + GLS + CAC) achieved an AUC of 0.91, outperforming hs-cTnI + LVEF (0.83) and LVEF alone (0.66). The MY-CARD score stratified 12-month CTRCD risk into low (6.2%), intermediate (28.7%), and high (71.4%) categories. Patients with both hs-cTnI elevation and GLS worsening had the highest subsequent CTRCD risk (adjusted HR 5.42–7.86). Conclusions Integrating baseline hs-cTnI, GLS, and CAC improved CTRCD risk stratification in myeloma patients. The MY-CARD score provides a practical framework for baseline and on-treatment risk assessment, supporting closer surveillance in high-risk patients. External validation and prospective studies are warranted.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) conducted an observational in Multiple myeloma (n=312). Integration of baseline hs-cTnI, GLS, and CAC (MY-CARD score) vs. Conventional LVEF surveillance was evaluated on Prediction of cancer therapy-related cardiac dysfunction (CTRCD) at 12 months (AUC 0.91, 95% CI 0.87-0.94, p=<0.001). Integrating baseline high-sensitivity cardiac troponin I, global longitudinal strain, and coronary artery calcium improved risk stratification for cancer therapy-related cardiac dysfunction, achieving an AUC of 0.91 compared to 0.66 for ejection fraction alone.
Synapse has enriched 10 related papers. Consider them for comparative context: